half of pregnancy puts the fetus at high risk of having minimal B cells at delivery There is no available evidence regarding use or safety of the new small-molecule agents, tofacitinib, baricitinib, and apremilast, during pregnancy. The Voting Panel elected not to offer recommendations regarding these drugs. It should be noted, however, that small molecules are likely to pass through the placenta. Medication use during breastfeeding. The benefits of breastfeeding are numerous Infant serum